Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Washington University School of Medicine
Study ID
NCT06926634
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • High Grade Neuroendocrine Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zanzalintinib — DRUG
    Provided by Exelixis

Study Details

The investigators hypothesize that zanzalintinib maintenance therapy after initial cytotoxic chemotherapy can prolong the progression-free survival (PFS) in patients with high-grade NENs.

Key Dates

Start date
Dec 9, 2025
Status verified
Dec 2025
Primary completion
Dec 31, 2034
Completion
Dec 31, 2034

Study Design

Enrollment
32 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Zanzalintinib
    Zanzalintinib 60 mg taken by mouth once daily in 28-day cycles for up to 3 years.

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: Through completion of follow-up (up to 6 years) ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Mayo Clinic - RochesterRochesterMinnesota55905
Thorvadur Haldanarson, M.D.
507-538-3270
Thorvardur Haldanarson, M.D. (PRINCIPAL_INVESTIGATOR)
Washington University School of MedicineSt LouisMissouri63110
Nikolaos Trikalinos, M.D.
[email protected]
314-273-4959
Nikolaos Trikalinos, M.D. (PRINCIPAL_INVESTIGATOR)
Esther Lu, Ph.D. (SUB_INVESTIGATOR)

Find similar trials in Rochester, MN

By research site
Mayo Clinic - Rochester· Rochester, MNWashington University School of Medicine· St Louis, MO